Jennifer Doudna Patents & Innovation Profile — PatSnap Eureka
Jennifer A. Doudna: Patent Portfolio & Innovation Analysis
Jennifer A. Doudna is a Nobel Prize-winning biochemist at the University of California, Berkeley, who co-developed CRISPR-Cas9 genome editing technology and holds 1,098 patents spanning RNA-guided genome editing, novel CRISPR effectors, therapeutic delivery, and CRISPR diagnostics. Her portfolio, primarily assigned to the Regents of the University of California and the Howard Hughes Medical Institute, represents one of the most commercially significant and legally scrutinised inventor profiles in the history of biotechnology, with foundational filings that underpin an entire global industry in precision genome editing.
Research Output by Citation Impact
Top cited papers show Doudna's highest-impact work spans 2013–2020, with the 2013 human cell editing paper reaching 1,138 citations.
Jennifer Doudna's Research & Patent Landscape
With 1,098 patents and 273 indexed papers, Doudna's portfolio spans foundational CRISPR-Cas9 mechanisms, novel effector discovery, and therapeutic translation — each domain generating dense IP activity from 2012 onward.
Citation Impact by Publication Year
The 2013 and 2014 papers on Cas9 activity in human cells are the most cited, each exceeding 1,000 citations and serving as foundational prior art for the entire CRISPR field.
Technology Domain Breakdown
CRISPR-Cas9 mechanism and specificity is the dominant domain, with novel effector discovery and therapeutic translation forming the two next-largest clusters.
Core Areas of Innovation
Jennifer Doudna's research spans four major technology clusters — from foundational CRISPR-Cas9 mechanism to next-generation effector discovery, precision editing, and clinical therapeutic delivery.
CRISPR-Cas9 Mechanism & Specificity
Core domainPatents and publications in this domain cover how Cas9 locates, binds, and cleaves target DNA sequences under guide RNA direction, including conformational dynamics, PAM recognition, and HNH nuclease domain checkpoints that control on-target versus off-target cleavage. Mechanistic insights directly inform claims around Cas9 variants with improved specificity and fidelity.
- RNA-programmed genome editing in human cells (2013)
- DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 (2014)
- Conformational control of DNA target cleavage by CRISPR–Cas9 (2015)
Novel CRISPR Effectors: Cas12, Cas13, CasX & CasΦ
Expanding domainThis domain covers the discovery and functional characterisation of CRISPR effectors beyond Cas9, including Cas12a's RNA-triggered single-stranded DNase activity, the structural distinctiveness of CasX as a third class of RNA-guided genome editor, and CasΦ, a hypercompact nuclease capable of plant genome editing. Discovery of new CRISPR systems from uncultivated microbes expanded the scope of what can be claimed around non-Cas9 editing tools.
- CRISPR-Cas12a target binding unleashes single-stranded DNase activity
- CasX enzymes comprise a distinct family of RNA-guided genome editors (2019, 280 citations)
- New CRISPR–Cas systems from uncultivated microbes (2016, 459 citations)
Homology-Directed Repair & Precision Editing
Precision domainPatents in this cluster address the challenge of achieving precise genetic insertions rather than simple knockouts, covering controlled delivery timing to enhance HDR, Cas9 ribonucleoprotein delivery combined with AAV donor templates, and nanoparticle co-delivery of Cas9, guide RNA, and donor DNA in vivo. These findings are foundational to therapeutic genome editing strategies and carry substantial IP weight in the gene therapy space.
- Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery (2014, 749 citations)
- Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery
- Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo (2017, 562 citations)
Therapeutic Genome Editing & Clinical Translation
Clinical domainThis domain covers how CRISPR tools can be safely and efficiently introduced into human cells, including primary T cells, neurons, and immune system cells, addressing targeted delivery to immune cells for cancer immunotherapy, genome editing of bacteria within microbial communities, and programmable enveloped delivery vehicles for in vivo use.
- The promise and challenge of therapeutic genome editing (2020, 774 citations)
- Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs
- Programmable enveloped delivery vehicles for in vivo CRISPR delivery
CRISPR Diagnostics & Expanded Applications
Emerging domainEmerging from the Cas12 and Cas13 effector discoveries, this domain covers CRISPR-based diagnostic tools exploiting collateral nuclease activity, genome editing in agricultural and plant systems using CasΦ, CRISPR trimmer-integrase systems for genome expansion, and RNA-dependent RNA targeting applications. These represent the next generation of IP activity signalled by Doudna's most recent publications.
- Genome editing in plants using the compact editor CasΦ
- Genome expansion by a CRISPR trimmer-integrase
- RNA-dependent RNA targeting by CRISPR-Cas9 (2018, 171 citations)
Jennifer Doudna's Highest-Impact Research
With 273 indexed papers and individual citation counts exceeding 1,100, Doudna's literature record provides prior art reach across virtually every sub-domain of CRISPR technology.
| Title | Year | Citations | Primary Institution | Link |
|---|---|---|---|---|
| RNA-programmed genome editing in human cells | 2013 | 1,138 ↑ | UC Berkeley / HHMI / Lawrence Berkeley Natl Lab | View → |
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 | 2014 | 1,089 ↑ | UC Berkeley / Columbia University / HHMI | View → |
| The promise and challenge of therapeutic genome editing | 2020 | 774 ↑ | UC Berkeley / Innovative Genomics Institute / HHMI | View → |
| Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery | 2014 | 749 ↑ | UC Berkeley / HHMI / Lawrence Berkeley Natl Lab | View → |
| Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair | 2017 | 562 ↑ | UC Berkeley / Lawrence Berkeley Natl Lab / University of Tokyo | View → |
| New CRISPR–Cas systems from uncultivated microbes | 2016 | 459 ↑ | UC Berkeley / HHMI | View → |
| Conformational control of DNA target cleavage by CRISPR–Cas9 | 2015 | 326 ↑ | UC Berkeley / HHMI | View → |
| CasX enzymes comprise a distinct family of RNA-guided genome editors | 2019 | 280 ↑ | UC Berkeley / HHMI | View → |
Research Literature by Jennifer Doudna
273 papers indexed · Spanning RNA structural biology, CRISPR-Cas mechanisms, genome editing tool development, therapeutic applications, and CRISPR ethics and policy — an exceptional depth and citation density for any academic scientist.
| Title | Year | Citations | Venue / Source |
|---|---|---|---|
| RNA-programmed genome editing in human cells | 2013 | 1,138 ↑ | UC Berkeley / HHMI / Lawrence Berkeley Natl Lab |
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 | 2014 | 1,089 ↑ | UC Berkeley / Columbia University / HHMI |
| The promise and challenge of therapeutic genome editing | 2020 | 774 ↑ | UC Berkeley / Innovative Genomics Institute / HHMI |
| Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery | 2014 | 749 ↑ | UC Berkeley / HHMI / Lawrence Berkeley Natl Lab |
| Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair | 2017 | 562 ↑ | UC Berkeley / Lawrence Berkeley Natl Lab / University of Tokyo |
🔬 Mechanistic Biochemistry
Understanding precisely how CRISPR-Cas proteins locate, interrogate, and cleave nucleic acid targets, including foundational work on conformational dynamics, off-target behaviour, PAM sequence recognition, and the HNH nuclease domain checkpoint that governs cleavage fidelity.
🧬 CRISPR Tool Discovery & Engineering
Identifying new Cas proteins from environmental metagenomics, engineering improved variants for specificity and compact size, and characterising RNA-targeting effectors such as Cas13 — directly expanding the scope of patentable CRISPR technology beyond the original Cas9 framework.
💊 Therapeutic Translation
Addressing delivery, immune response, HDR efficiency, and the ethics of clinical genome editing — including the field's most widely read survey on therapeutic opportunities (2020, 774 citations) and pioneering work on in vivo CNS editing and immune cell targeting for cancer immunotherapy.
Why Jennifer Doudna's Portfolio Matters
Strategic implications for patent attorneys, in-house IP teams, R&D strategists, and licensing executives operating in the life sciences.
FTO Considerations
Freedom-to-operate analysis in any CRISPR-related domain requires careful mapping of UC Berkeley's patent estate arising from Doudna's group. The interference and inter partes review proceedings between the Broad Institute and UC Berkeley over CRISPR-Cas9 — covering guide RNA design, Cas9 variants, delivery modalities, and specific therapeutic applications — reflect the enormous commercial stakes of inventorship and claim scope. Any FTO analysis in genome editing must account for the layered claims across this contested landscape.
Prior Art Depth
With 273 indexed publications and citation counts reaching above 1,100 on individual papers, Doudna's literature record provides prior art reach across virtually every sub-domain of CRISPR technology. For applicants filing in adjacent areas — including base editing, prime editing, epigenome editing, CRISPR diagnostics, or RNA targeting — a thorough prior art search must include her group's pre-2015 publications, which establish foundational disclosure well before many competitor applications.
Jennifer Doudna Patent Portfolio: Key Questions
Analyse Jennifer Doudna's Full Patent Landscape
Search 208M+ patents and 300M+ papers to map CRISPR-Cas9 IP, conduct FTO analysis, and identify licensing opportunities — all in PatSnap Eureka IP.
References & External Resources
- 1. RNA-programmed genome editing in human cells (2013) — PatSnap Eureka Literature
- 2. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9 (2014) — PatSnap Eureka Literature
- 3. The promise and challenge of therapeutic genome editing (2020) — PatSnap Eureka Literature
- 4. USPTO Patent Search — www.uspto.gov
- 5. European Patent Office — www.epo.org
- 6. WIPO Patent Database (PatentScope) — www.wipo.int
- 7. PatSnap Eureka IP Platform — eureka.patsnap.com
PatSnap Eureka searches 208M+ patents and papers to answer instantly.